Literature DB >> 17515961

Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Naoki Fujita1, Ryosuke Sugimoto, Masaki Takeo, Naohito Urawa, Rumi Mifuji, Hideaki Tanaka, Yoshinao Kobayashi, Motoh Iwasa, Shozo Watanabe, Yukihiko Adachi, Masahiko Kaito.   

Abstract

Patients with chronic hepatitis C frequently have serum and hepatic iron overload, but the mechanism is unknown. Recently identified hepcidin, exclusively synthesized in the liver, is thought to be a key regulator for iron homeostasis and is induced by infection and inflammation. This study was conducted to determine the hepatic hepcidin expression levels in patients with various liver diseases. We investigated hepcidin mRNA levels of liver samples by real-time detection-polymerase chain reaction; 56 were hepatitis C virus (HCV) positive, 34 were hepatitis B virus (HBV) positive, and 42 were negative for HCV and HBV (3 cases of auto-immune hepatitis, 7 alcoholic liver disease, 13 primary biliary cirrhosis, 9 nonalcoholic fatty liver disease, and 10 normal liver). We analyzed the relation of hepcidin to clinical, hematological, histological, and etiological findings. Hepcidin expression levels were strongly correlated with serum ferritin (P < 0.0001) and the degree of iron deposit in liver tissues (P < 0.0001). Hepcidin was also correlated with hematological parameters (vs. hemoglobin, P = 0.0073; vs. serum iron, P = 0.0012; vs. transferrin saturation, P < 0.0001) and transaminase levels (P = 0.0013). The hepcidin-to-ferritin ratio was significantly lower in HCV(+) patients than in HBV(+) patients (P = 0.0129) or control subjects (P = 0.0080). In conclusion, hepcidin expression levels in chronic liver diseases were strongly correlated with either the serum ferritin concentration or degree of iron deposits in the liver. When adjusted by either serum ferritin values or hepatic iron scores, hepcidin indices were significantly lower in HCV(+) patients than in HBV(+) patients, suggesting that hepcidin may play a pivotal role in the pathogenesis of iron overload in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515961      PMCID: PMC1869620          DOI: 10.2119/2006-00057.Fujita

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  44 in total

1.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice.

Authors:  G Nicolas; M Bennoun; I Devaux; C Beaumont; B Grandchamp; A Kahn; S Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis.

Authors:  R E Fleming; M C Migas; C C Holden; A Waheed; R S Britton; S Tomatsu; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

3.  Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo.

Authors:  H Kawabata; R S Germain; P T Vuong; T Nakamaki; J W Said; H P Koeffler
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

4.  A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron.

Authors:  Chizu Koyama; Shinya Wakusawa; Hisao Hayashi; Toshio Ueno; Rie Suzuki; Motoyoshi Yano; Hiroshi Saito; Toru Okazaki
Journal:  Intern Med       Date:  2005-09       Impact factor: 1.271

5.  The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.

Authors:  D Thorburn; G Curry; R Spooner; E Spence; K Oien; D Halls; R Fox; E A B McCruden; R N M MacSween; P R Mills
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Hepcidin, a urinary antimicrobial peptide synthesized in the liver.

Authors:  C H Park; E V Valore; A J Waring; T Ganz
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

7.  A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload.

Authors:  C Pigeon; G Ilyin; B Courselaud; P Leroyer; B Turlin; P Brissot; O Loréal
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

8.  Hemochromatosis with HFE gene mutation in a Japanese patient.

Authors:  T Sohda; R Okubo; S Kamimura; T Ohkawara
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

9.  LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity.

Authors:  A Krause; S Neitz; H J Mägert; A Schulz; W G Forssmann; P Schulz-Knappe; K Adermann
Journal:  FEBS Lett       Date:  2000-09-01       Impact factor: 4.124

10.  New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.

Authors:  A Roetto; A Totaro; A Piperno; A Piga; F Longo; G Garozzo; A Calì; M De Gobbi; P Gasparini; C Camaschella
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

View more
  73 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels.

Authors:  Oya Yonal; Filiz Akyuz; Kadir Demir; Sevgi Ciftci; Fahriye Keskin; Binnur Pinarbasi; Ahmet Uyanikoglu; Halim Issever; Sadakat Ozdil; Gungor Boztas; Fatih Besisik; Sabahattin Kaymakoglu; Yilmaz Cakaloglu; Zeynel Mungan; Atilla Okten
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

3.  Inhibition of hepcidin transcription by growth factors.

Authors:  Julia B Goodnough; Emilio Ramos; Elizabeta Nemeth; Tomas Ganz
Journal:  Hepatology       Date:  2012-06-18       Impact factor: 17.425

4.  Molecular mechanism of iron metabolism and overload in chronic hepatitis C.

Authors:  Masahiko Kaito
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

Review 5.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 6.  Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2018-05-31       Impact factor: 11.848

Review 7.  [Current problems of hepatitis].

Authors:  H P Dienes; U Drebber
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

8.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

Review 9.  The role of iron in the pathophysiology and treatment of chronic hepatitis C.

Authors:  Leslie Price; Kris V Kowdley
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

10.  Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.

Authors:  Wei-Hong Hou; Lisa Rossi; Ying Shan; Jian-Yu Zheng; Richard-W Lambrecht; Herbert-L Bonkovsky
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.